【美股财报】Mind Medicine (MindMed) Inc 2025年季度报告.pdf

Blueprint Medicines Corp 2024年度报告

How Off-Label Use of Medicines Drives Health-Care Use and Disability

Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines

Annex 1 Socio-Economic Analysis Of the potential restriction of the perand polyfluoroalkyl substances (PFAS) used in the production, packaging and delivery of human medicinal products

Clearmind Medicine Inc 2025年年度报告和过渡报告

Medicine shortages: EFPIA proposal for action

Position on the Use of Artificial Intelligence in the Medicinal Product Lifecycle

Prime Medicine Inc 2024年度报告

Disc Medicine Inc 2024年度报告

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors